Phase 1 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with advanced lung cancer or another solid tumour where a tissue sample (biopsy) can be taken
- People whose doctors estimate they are likely to live for more than 12 weeks
- People whose liver function scores within a certain healthy range (a measure called the Child-Pugh-Turcotte score must be below 7 — confirm with trial site)
- People whose heart, lungs, liver, and kidneys are all functioning at an adequate level
- People whose specially prepared immune cells (T cells), made from their own blood, have been successfully modified in the laboratory to meet specific activity thresholds set by the trial
- People who have read, understood, and signed an informed consent form, or whose legal guardian has done so on their behalf
Who may not be able to join:
- People who have previously received any form of gene therapy
- People whose tumour measures more than 25 cm in size
- People with a serious viral infection such as hepatitis B (HBV), hepatitis C (HCV), or HIV
- People with a known positive HIV diagnosis
- People who have had a lung transplant in the past
- People who currently have an active infection caused by bacteria, a virus, or fungi
- People who are currently taking steroid medications at a daily dose of 0.5 mg of prednisone (or equivalent) per kilogram of body weight or higher
- Women who are pregnant or currently breastfeeding
- People with other serious medical conditions that the trial doctors consider make participation unsuitable
- People with any other circumstances that the trial doctors consider make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhenfeng Zhang, MD,PhD, Second Affiliated Hospital of Guangzhou Medical University
Phone: 0086-020-34153532
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Patients with Dose Limiting Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.